A
pproximately 50% of patients with heart failure (HF) have preserved ejection fraction (EF; HFpEF), a proportion which continues to increase. 1 Patients with HFpEF have a poor prognosis with a median survival of ≈2 years and 5-year mortality of ≈75%.
2 HFpEF is often described as single largest unmet need in cardiovascular medicine largely because of the complex phenotypes and the enigmatic nature of disease pathogenesis. 3 Multiple associated comorbidities (hypertension, obesity, diabetes mellitus, old age, and renal dysfunction) and clinical phenotypes (diastolic dysfunction, pulmonary hypertension, atrial fibrillation, and chronotropic incompetence) have complicated the understanding of HFpEF. 4 Unlike HF with reduced EF (HFrEF), where multiple therapeutic agents have been shown to improve survival, all drugs or devices tested rigorously to date have failed in patients with HFpEF. 5, 6 Cardiovascular death accounts for ≈60% of all deaths, and sudden death is the leading mode of exodus, comprising 25% of all mortality in HFpEF patients. [6] [7] [8] Although cardiac arrhythmias often underlie sudden death mechanistically, there is no known link between arrhythmias and sudden death in HFpEF. 9 Relevant clinical data are lacking, perhaps because patients with HFpEF rarely have implanted devices which record heart rate. We thus turned to the Dahl salt-sensitive (DSS) rat model of HFpEF to investigate sudden death. This model develops delayed repolarization, easily-inducible ventricular arrhythmias (VA), and premature death. 10 
METHODS
The data, analytic methods, and study materials will be/ have been made available to other researchers for purposes of reproducing the results or replicating the procedure.
Rat Model of HFpEF
All animal experiments were approved by the Cedars-Sinai Institutional Animal Care and Use Committee. Figure 1A depicts the implementation of the DSS rat model of HFpEF. [11] [12] [13] In brief, 7-week-old male DSS rats (Charles River Laboratories, MA) were randomly assigned to a high-salt (HS) diet (AIN-76A+8% NaCl with irradiation, Research Diets, NJ) to induce HFpEF (n=13) or to a normal-salt diet (AIN-76A [0.3% NaCl] with irradiation) to serve as controls (n=9). Transthoracic echocardiography was performed to measure systolic and diastolic function between 14 and 18 weeks of age. HS-fed DSS rats showed signs of HF from 14 to 15 weeks of age, which were scored as follows: appearance (0: normal; 1: mild distress; 2: severe distress), breathing (0: normal; 1: mild tachypnea; 2: labored breathing), mobility (0: normal; 1: decreased activity; 2: severely diminished), edema (0: normal; 1: mild edema; 2: severe edema), and weight (0: >360 g; 1: 300 g < < 360 g; 2: <300 g; Figure 1E ). HS-fed rats with echo-verified diastolic dysfunction, normal EF (>50%), and signs of HF were diagnosed with HFpEF and used for experiments. HS rats that failed to meet these criteria (≈10% because of absence of diastolic dysfunction or reduced EF) were excluded and omitted from analysis.
Transthoracic Echocardiogram
Rats were anesthetized with 2% isoflurane for transthoracic echocardiography (Vevo 770, VisualSonics, Toronto, Canada). Systolic function was measured with EF from images obtained in the parasternal short axis view as described.
14 Diastolic function was evaluated from the apical 4-chamber views by measuring E/A and E/E′ ratios. [11] [12] [13] [14] E and A waves were measured with pulse wave Doppler mode between the tips of the mitral valve.
11-14 E′ and A′ waves were measured with tissue Doppler mode at the septal corner of the mitral annulus.
14 Three separate measurements from each animal were averaged.
Telemetry Device Implantation
Control and HFpEF rats were induced with 5% and maintained with 2% isoflurane for intraperitoneal telemetry device (CTA-F40, Data Sciences International, St. Paul, MN) implantation via an abdominal incision. The 2 device electrodes were sutured subcutaneously in a lead II configuration (negative electrode: right upper chest; positive electrode: left lower abdomen). Telemetry data were analyzed using Ponemah software (Data Sciences International). Premature ventricular contractions (PVC) were checked every 10 minutes and averaged for hourly PVC burden and 24-hour PVC burden. PVC were graded per Lown grading system (0: no PVC; 1: occasional PVC [<30 per hour]; 2: frequent PVC [>30 per hour]; 3: multiform PVC; 4: repetitive PVC; 5: R-on-T PVC). ECG parameters (QT interval, QTc interval, RR interval, P wave, PR interval, and QRS width) were measured 3× and averaged. Heart rate was measured every 10 minutes for 24 hours to calculate SD of average NN interval. Continuous recording of NN interval for 5 minutes was used to check time and frequency domains of heart rate variability (HRV), such as SD of NN interval, SD1/ SD2 from Poincare plots, and fast Fourier transform analysis of low frequency (0.2-0.8 Hz) and high frequency (0.8-2.5 Hz). VA were defined as either ventricular tachycardia (VT, >3 consecutive ventricular beats, >600 bpm) or ventricular fibrillation. Sustained VA were defined as lasting >30 seconds while nonsustained <30 seconds.
WHAT IS KNOWN?
• Sudden death is the leading mode of death (≈25%) in patients with heart failure with preserved ejection fraction.
• The underlying mechanisms of sudden death in heart failure with preserved ejection fraction are largely unknown.
WHAT THE STUDY ADDS?
• In a rodent model of heart failure with preserved ejection fraction, sudden death was common and generally associated with ventricular arrhythmias.
• Heart failure with preserved ejection fraction rats showed increased burden of premature ventricular contractions and reduced heart rate variability.
Survival Analysis
Survival was monitored from device implantation through study end point (up to 26 weeks). Comparative medicine staff monitored rats twice a day and either recorded unexpected deaths or flagged sick animals for prompt euthanasia. Common reasons were weakness (inability to reach water and chow), corporal edema, and seizure. Sudden death was defined as death occurring within 24 hours of last being reported alive.
Statistical Analysis
Continuous variables are shown as mean±SD, and categorical variables are presented as numbers (percentages). Normal distribution was assessed using Kolmogorov-Smirnov test, and homogeneity of variance was tested by Levene test. Student t test was used for the comparison of variables with normal distribution while Mann-Whitney test was used for the comparisons of non-normally distributed variables. Fisher exact test was used to compare categorical variables. Kaplan-Meier analysis was used to check survival with log-rank test. Two-tailed P value was used to assess statistical significance (*P<0.05 and **P<0.001). SPSS v24. software was used for statistical analysis.
RESULTS

Development of HFpEF
HS-fed DSS rats showed diastolic dysfunction as evidenced by decreased E/A ratio (1.17±0.17 versus 1.62±0.23 in controls; P<0.001; Figure 1C ; Figure IB in the Data Supplement) and increased E/E′ ratio (16.4±2.8 versus 11.9±2.8 in controls; P<0.05; Figure 1D ; Figure IC in the Data Supplement) from echocardiography at 14 to 15 weeks of age. EF was preserved in both experimental groups (67%±7% versus 67%±5% in controls; P=0.94; Figure 1B ; Figure A, Dahl salt-sensitive rats were fed a high-salt (HS) or normal-salt (NS) diet from 7 wk of age. Echocardiography was performed to assess ejection fraction (EF), E/A ratio, and E/E′ ratio by 14 to 15 wk of age. Telemetry devices were implanted to echo-proven HFpEF and control rats. Survival was monitored to identify sudden death. B, EF was preserved in HFpEF rats, as well as in controls. C, E/A ratio was reduced in HFpEF rats compared with controls. D, E/E′ ratio was increased in HFpEF rats compared with controls. E, HF score was calculated from the following parameters: appearance, breathing, mobility, edema, and weight. F, The HF score was increased in HFpEF rats compared with controls.
was calculated from the following parameters: appearance, breathing, mobility, edema, and weight ( Figure 1E ). The HF score was increased in HS-fed rats (2.8 versus 0 in controls; P<0.001; Figure 1F ). Echo-proven HS-fed rats with at least 1 sign of HF were diagnosed with HFpEF.
Increased PVC Burden
Rats with HFpEF appeared to have more frequent PVCs, and PVCs which were more complex, than did control rats, but the differences were not statistically significant ( Figure ID -IK in the Data Supplement).
Delayed Repolarization
Delayed repolarization was evident in HFpEF rats (Figure 2A) : the QT interval was prolonged to 105±3 ms from 83±2 ms in controls (P<0.001; Figure 2B ). QTc interval (calculated as QT interval divided by square root of RR interval) was also prolonged (248±7 versus 199±5 ms in controls; P<0.001; Figure 2C ). RR interval was not different between the 2 groups nor were P wave, PR interval, or QRS width ( Figure 2D-2G ).
Decreased Heart Rate Variability
Averaged heart rate was measured in control and HFpEF rats for 24-hour period ( Figure 
Spontaneous VA
Spontaneous VA were noted during telemetry in HFpEF rats but not in controls ( Figure 3A) . In total, 6 HFpEF rats developed spontaneous VA (6/13=46.1 versus 0/9=0% in controls; P<0.05; Figure 3B ). The 6 HFpEF rats were between 17 and 19 weeks of age. Electrolytes (Na, K, and Ca), pH from arterial blood, and creatinine were all within normal limits in HFpEF rats ( Figure IIJ -IIN in the Data Supplement). Half of them (3/6=50%) were nonsustained VA (<30 seconds) while the rest lasted >30 seconds (Figure 3C ). Three of 6 rats developed monomorphic VT (all 
Sudden Death
Control and HFpEF rats were monitored until 26 weeks of age. Although there was not a single death in controls, all HFpEF rats died by 26 weeks of age (log-rank <0.001; Figure 4A) . Reasons of mortality were either sudden death or mandated euthanasia because of weakness (inability to reach water and chow), severe corporal edema, or seizure activity ( Figure 4B ). Sudden death occurred in 4 of 13 HFpEF rats. Telemetry at the time of death showed VA as the cause in 3 of 4 cases ( Figure 4C ; Figure IIIA and IIIB in the Data Supplement). The durations of VA preceding sudden death were 44, 62, and 81 seconds. One sudden death case showed prolonged ST depressions followed by bradycardic death ( Figure 4D) ; although this pattern looks ischemic, coronary disease is not a known feature of the DSS model. Further comparison between 9 nonsudden death rats and 4 sudden death rats did not reveal any significant differences in terms of HF score, QTc prolongation, or parameters of HRV. Such an analysis would require a large number of animals ( Figure IVA 
DISCUSSION
Sudden death is the most common mode of exodus in HFpEF; however, the pathogenesis of sudden death in this patient population is not well-understood. Here, we have tested the hypothesis that VA precipitates sudden death in HFpEF rats. Ambulatory recordings revealed delayed repolarization (QTc prolongation) and spontaneous VA in HFpEF rats but not in controls. Approximately 30% of HFpEF rats died suddenly and 75% of ambulatory recordings during sudden death revealed underlying VA. HRV was reduced in HFpEF rats, which is a well-known predictor of arrhythmic death in HF. 15 Our translational experiments support the hypothesis that VA precipitates sudden death in DSS rats with HFpEF.
Relative to HFrEF, HFpEF has historically received far less attention from either clinicians or basic scientists. Meanwhile, HFpEF has risen epidemically to comprise about half of all HF cases. 1, 16 In HFrEF, ≈45% of deaths are sudden and unexpected although this percentage is trending down because of advances in medical and device therapy. 17 Cardiac arrhythmias are responsible for most sudden death cases in HFrEF, 18, 19 but this conjecture is speculative in HFpEF because of the absence of relevant studies. Patients with HFpEF have a poor prognosis with a median survival of 2 years, and sudden death is the most common mode of death. 2 In the I-Preserve trial, 60% of deaths were cardiovascular in HFpEF patients, with the following breakdown (as percent of all deaths): 26% sudden, HF (14%), cerebrovascular accident (9%), and myocardial infarction (5%). 7 In the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist), 63.9% of all deaths in HFpEF patients were cardiovascular. 6 Sudden death was the most common mode of death accounting for 24.3%, followed by HF (12.7%), myocardial infarction (6.3%), and stroke (4.8%). Although sudden deaths are mostly cardiac and often assumed to have been caused by lethal arrhythmias, 19 the cause in any given case is unknown unless heart rhythm is fortuitously recorded. Given that lethal arrhythmias are responsible for most sudden deaths, VT or fibrillation will be to blame in most cases, especially in the case of structural cardiac abnormality, such as HF. 9, 19 Although some studies suggest that pulseless electrical activity or asystole is more common than VT or fibrillation in the case of cardiac arrest, as in the general population or in-hospital cardiac arrest, this may not be true in patients with HF. 20 Our study is the first to implicate VA as cause of sudden death in HFpEF. A variety of hypotheses have been suggested to explain the increased incidence of VA and sudden death in HF. These include prolonged repolarization, abnormal calcium homeostasis, increased fibrosis, decreased conduction, autonomic nervous system imbalance, and altered neurohumoral signaling. 19, [21] [22] [23] Our recent preclinical study demonstrated delayed repolarization underlying high VA inducibility in the same rat model of HFpEF. 10 Action potentials were prolonged, and multiple reentry circuits were responsible for an increased tendency to VA in HFpEF rats. Increased myocardial fibrosis further promoted multiple reentry circuits. Although our previous study generated proposed mechanisms of VA in HFpEF, we did not record spontaneous VA nor did we verify that VA actually causes sudden death. By implanting telemetry devices, we have shown here that HFpEF rats not only develop spontaneous VA but they also die suddenly because of spontaneous VA. Systematic rhythm monitoring in HFpEF populations will be required to determine if our findings have any clinical correlates.
HRV has long been investigated as an independent predictor of sudden death in HF. 24 Our data are consistent with previous clinical reports that decreased HRV predicts sudden death in HF. 15 Although HRV was reduced in HFpEF rats, it did not correlate with individual sudden death risk, perhaps because of the low number of animals studied.
Study Limitations
Our experimental study has several limitations. First, this model has been critiqued as being an admixture of HFpEF and HFrEF. 25 Here, we have phenotypically verified the diagnosis of HFpEF in all animals enrolled, removing the potential uncertainty. In addition, we have shown evidence of preserved EF when these rats are euthanized because of weakness or seizures. Although we have not measured EF in sudden death rats (because of the sudden nature), in view of our previous observation that these HFpEF rats maintain preserved EF, our observations provide valuable translational insights into the mechanisms of sudden death in HFpEF. Second, even if HFpEF has been well-validated, this rat model might not truly capture the pathology of human HFpEF. Patients with HFpEF often have multiple comorbidities, such as obesity, diabetes mellitus, coronary artery disease, chronic kidney disease, atrial arrhythmias, and old age. Although it will be difficult or almost impossible to induce multiple comorbidities, we think our model reproduces many important clinical features typical of human HFpEF: hypertension, hypertrophy, diastolic dysfunction, delayed repolarization, increased mortality, and sudden death. Third, sudden death in rodents might not reflect the features of sudden death in humans. Currently, there is no study investigating the causes of sudden death in human HFpEF. The hypothesis that VA commonly underlie sudden death can only be tested systematically in humans by using dedicated ambulatory recordings; the present findings have potential value in motivating such studies in HFpEF patients. Fourth, although HRV is a useful predictor of sudden death in HFrEF, 15 it is not being clinically used to screen HFpEF patients. Further investigations are needed to test whether HRV might be useful in predicting sudden death in HFpEF patients. 
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